Skip to main content

A single-arm phase II trial of Selective Avoidance of nodal VolumEs at minimal Risk (SAVER) in the contralateral N0 neck of patients with p16-positive oropharynx cancer

In brief

SAVER radiation had zero opposite-neck nodal failures in 52 patients

In this single-arm phase II trial, 52 patients with p16-positive oropharyngeal cancer received reduced radiation to the uninvolved opposite-side neck; none had a nodal failure there during a median 31 months of follow-up. The approach also lowered radiation dose to the opposite parotid gland, but the small study and lack of a comparison group leave its safety and benefits for broader use uncertain.

Journal
International journal of radiation oncology, biology, physics (Q1)
Published
18 November 2026
Study design
Non-randomized / quasi-experimental trial
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Jason K Molitoris, Matthew E Witek, Matthew J Ferris, Akshar Patel, Rebecca F Krc, Jenna Jatczak, et al.
PMID
43051602
DOI
10.1016/j.ijrobp.2026.10.061

Why clinicians should know about it

  • Picked for Radiation Oncology (paper of the day, 19 November 2026): Phase II elective neck-volume reduction; regional control and organ sparing

Abstract

PURPOSE: To report a single arm multi-site phase II study evaluating a reduced contralateral neck elective nodal clinical target volume (enCTV) in p16+ oropharyngeal cancer (p16+OPC). METHODS AND MATERIALS: Newly diagnosed p16+OPC without contralateral nodal involvement but with clinical or pathological features warranting contralateral elective nodal treatment were eligible. Treatment included proton- or photon-based definitive (chemo)radiation or adjuvant (chemo)radiation following Transoral Robotic Surgery. All patients received SAVER enCTV and the primary endpoint was two-year elective out-of-field contralateral nodal failure. Dosimetric comparison between SAVER enCTV and consensus enCTV of the first 10 definitive and adjuvant patients was performed. Overall survival (OS), progression-free-survival (PFS), toxicities, and patient reported outcomes were analyzed. RESULTS: Fifty-two patients were enrolled, of which 36 (69.2%) received definitive (chemo)radiation. Thirty-five (67.3%) had bulky or multiple ipsilateral lymph nodes and 18 (34.6%) had significant smoking history. With median follow-up of 31.0 months (range 13 - 49 months), there were no contralateral nodal failures with an upper limit one-sided 95% confidence interval for contralateral nodal failure of 2.7%. Two-year OS and PFS were 92.2% (95% CI [88.5 - 95.9%]) and 86.2% (95% CI [81.4 - 91.0%]), respectively. Dosimetric comparison demonstrated decreased mean dose (18.3 Gy to 14.1 Gy [p=0.001]) and V30 Gy (20.8% to 11.6% [p=0.003]) to the contralateral parotid with SAVER enCTV. Acute grade 3 toxicity was observed in 13 (25%) patients including 8 (15.4%) who received a gastrostomy tube. There were no grade 4-5 toxicities. CONCLUSION: Selective avoidance of nodal volumes at minimal risk in the N0 contralateral neck can be safely performed while maintaining excellent regional control in the definitive and adjuvant settings. Dose to contralateral organs at risk and toxicity outcomes were favorable.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.